Appili Therapeutics Q4 Loss Narrows Amid Increase in Government Assistance
Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.
Appili Therapeutics Signs Definitive Agreement to Be Acquired by Aditxt, Inc.
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan
Appili Therapeutics Brief: As of September 30, 2023, Co Had Cash of $0.4 Million, Compared to $2.5 Million on March 31, 2023.
Appili Therapeutics Brief: Net Loss and Comprehensive Loss of $1.0 Million or $0.01 Loss per Share for the Three Months Ended September 30, 2023
Appili Therapeutics Brief: Announcing U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Brief: Also Noted Government Funding Committed to Enable Appili to Advance Its Biodefense Vaccine Candidate ATI-1701 Towards an IND
Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics Secures Contract for ATI-1701 Funding From U.S. Air Force Academy
Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Analysts Issue Forecasts for Appili Therapeutics Inc.'s FY2023 Earnings (TSE:APL)
Appili Therapeutics Inc. (TSE:APL) Forecasted to Post FY2023 Earnings of ($0.10) Per Share
Appili Therapeutics Inc. Forecasted to Post Q1 2023 Earnings of ($0.03) Per Share (TSE:APL)
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
BRIEF-Appili Therapeutics Reports Financial And Operational Results For Second Quarter Of Fiscal Year 2022 And Change Of Chief Financial Officer
Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial
Appili Therapeutics Says Phase 3 PRESECO Clinical Trial Did Not Meet Primary Endpoint